RxDoctor Payments Data

Dianna Boyer, MD

Internal Medicine · Camby, INNPI 1013919695

Payments from drug & device makers

$685in general payments, 2019–2025

Across 42 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$219
  • GSK$130
  • Novo Nordisk$130
  • Amgen$48
  • Lilly USA, LLC$42
  • AstraZeneca$23
  • plus $92 from 7 others

What the payments were for

  • Food & beverage$48771%
  • Education$19829%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$685 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$219,367
Medicare patients
346
Services billed
4,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$137,708
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$107,086
MounjaroTirzepatide71$96,782
JardianceEmpagliflozin80$93,521
EliquisApixaban68$79,002
XareltoRivaroxaban56$61,817
RybelsusSemaglutide28$55,563
FarxigaDapagliflozin Propanediol55$51,221
TrulicityDulaglutide15$38,366
MyrbetriqMirabegron41$32,492
JanuviaSitagliptin Phosphate34$31,133
WegovySemaglutide15$25,086
TradjentaLinagliptin12$19,392
Breo ElliptaFluticasone/Vilanterol33$19,331
ProliaDenosumab11$19,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$130$218,357118 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta$130$160,768177 claims
Lilly USA, LLCMounjaro, Trulicity$42$135,14986 claims
Boehringer IngelheimJardiance, Tradjenta$11$112,91392 claims
PfizerEliquis, Premarin$14$83,73279 claims
AstraZenecaFarxiga, Breztri Aerosphere$23$60,84270 claims
Astellas Pharma US IncMyrbetriq$219$32,49241 claims
AmgenProlia$48$19,14411 claims
AbbVieSynthroid$16$4,28081 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Camby

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →